跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CD123 CAR-T cells
首页
药物
CD123 CAR-T cells
CD123 CAR-T cells
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CAR T-CELLS COMPRISING AN ANTI CD33, AN ANTI CLL1 AND AT LEAST ONE FURTHER CAR ANTI CD123 AND/OR FTL3
US 2023330139 A1
申请人: AUTOLUS LTD
优先权: 2018
EP
US
WO
4 件公开
BISPECIFIC IN TANDEM RECEPTOR CAR AND METHOD FOR MODULATING THE TUMORAL MICROENVIRONMENT
EP 3908613 A4
申请人: CELLURIS PARTICIPACOES LTDA
优先权: 2019
EP
US
WO
4 件公开
EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS
EP 3744736 A1
申请人: NOVARTIS AG
优先权: 2013
EP
US
4 件公开
Components and methods for treating acute myelogenous leukemia
CN 116850210 A
申请人: UNIV WUHAN
优先权: 2023
CN
2 件公开
Multi-target combined CAR (chimeric antigen receptor)-T cell preparation and preparation method
CN 106822184 A
申请人: LIANG AIBIN
优先权: 2016
CN
Targeting T lymphocyte and preparation method and application thereof
CN 110157678 A
申请人: SHENZHEN BINDE BIOTECHNOLOGY CO LTD
优先权: 2018
CN
CD123-binding chimeric antigen receptors
US 11976121 B2
申请人: H LEE MOFFITT CANCER CT & RES
优先权: 2018
US
CAR-CD123T2 chimeric antigen receptor T cell and application thereof
CN 110904048 A
申请人: HEFEI CAS STEM REGENERATIVE MEDICINE CO LTD
优先权: 2019
CN
Chimeric antigen receptor targeting CD123 and CD7 and application thereof
CN 116041535 A
申请人: HEBEI SENLANG BIOTECHNOLOGY CO LTD
优先权: 2022
CN
NKG2D EXPRESSING CAR-T CELLS
US 20250302878 A1
申请人: H LEE MOFFITT CANCER CT & RES
优先权: 2023
US
第 1 / 2 页
上一页
下一页
药物
反馈